Rare Neuroendocrine Tumours and Cancers of Endocrine Organs
|
|
|
- Angela Snow
- 6 years ago
- Views:
Transcription
1 Rare Neuroendocrine Tumours and Cancers of Endocrine Organs 1. Neuroendocrine Tumours 1.1 General Results Table 1. Neuroendocrine Tumours: Incidence, Trends, Survival Flemish Region Both Sexes Incidence Trend EAPC Survival R/C N CR WSR Avg Age % p-value N at risk 5yr (%) NEUROENDOCRINE TUMOURS C 3, , Well differentiated endocrine tumours, carcinoid R Well differentiated endocrine tumours, atypical carcinoid R * * 13 * Well differentiated not functioning endocrine carcinoma of pancreas and digestive tract R 2, , Well differentiated functioning endocrine carcinoma of pancreas and digestive tract R * Poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) R Mixed endocrine-exocrine carcinoma R * Endocrine carcinoma of thyroid gland R Endocrine carcinoma of skin R Males EAPC Relative survival R/C N CR WSR Avg Age % p-value N at risk 5yr (%) NEUROENDOCRINE TUMOURS R 1, , Well differentiated endocrine tumours, carcinoid R Well differentiated endocrine tumours, atypical carcinoid R * * 5 * Well differentiated not functioning endocrine carcinoma of pancreas and digestive tract R Well differentiated functioning endocrine carcinoma of pancreas and digestive tract R * * 9 * Poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) R Mixed endocrine-exocrine carcinoma R * * 9 * Endocrine carcinoma of thyroid gland R Endocrine carcinoma of skin R Females EAPC Relative survival R/C N CR WSR Avg Age % p-value N at risk 5yr (%) NEUROENDOCRINE TUMOURS C 2, , Well differentiated endocrine tumours, carcinoid R Well differentiated endocrine tumours, atypical carcinoid R * * 8 * Well differentiated not functioning endocrine carcinoma of pancreas and digestive tract R 1, Well differentiated functioning endocrine carcinoma of pancreas and digestive tract R * * 14 * Poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) R Mixed endocrine-exocrine carcinoma R * * 14 * Endocrine carcinoma of thyroid gland R Endocrine carcinoma of skin R R/C: Rare or common CR: Crude rate (N/100,000 person years) WSR: age-standardised rate, using the world population (N/100,000 person years) EAPC: estimated annual percentage change RS: relative survival AvgAge: average age at diagnosis 1
2 1.2 Incidence 3,776 new neuroendocrine tumours are diagnosed in the Flemish Region between 2001 and The male/female (M/F) ratio is 0.9. RARECARE differentiates between seven rare entities: o 293 diagnoses of well-differentiated endocrine tumours, carcinoid are registered. This excludes tumours of skin, lung and digestive tract (M/F ratio = 1.4). 75% of these tumours have an unspecified primary site, thus a large contribution of primary lung, skin or digestive tract carcinoma cannot be excluded. o Only 17 well-differentiated endocrine tumours, atypical carcinoid are observed, this entity excludes lung, skin and digestive tract tumours (M/F ratio = 0.4). 11 are diagnosed without a specified primary site, thus primary lung, skin or digestive tract carcinoma cannot be excluded for these cases. o With 2,000 new cases of well-differentiated not functioning endocrine carcinoma of pancreas and digestive tract, this entity represents more than half of all rare neuroendocrine tumours (M/F ratio = 1.0). o Well-differentiated functioning endocrine carcinoma of pancreas and digestive tract represents 25 new cases (M/F ratio = 0.6). o 618 new diagnoses of poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) are observed (M/F ratio = 2.3). Half of all cases are registered with an unknown primary site, for these cases it cannot be excluded that lung or skin is the primary site. o Mixed endocrine-exocrine carcinoma accounts for 25 diagnoses, lung and skin carcinoma are excluded (M/F ratio = 0.8). o 164 endocrine carcinoma of thyroid gland are registered (M/F ratio = 0.8). o 322 new diagnoses of endocrine carcinoma of skin are registered (M/F ratio = 0.8). 2
3 Figure 1. Neuroendocrine Tumours: Age Specific Incidence by Sex and Sublocalisation Age specific incidence rates depend greatly on the type of endocrine carcinoma. The well-differentiated not functioning carcinoma of pancreas and digestive tract that already occur at an early age are predominantly incidental findings of carcinoid tumours of the appendix. 3
4 1.3 Trends Figure 2. Neuroendocrine Tumours: Age-Standardised Incidence A significant increase is observed for well-differentiated not functioning endocrine carcinoma of pancreas and digestive tract. 1.4 Survival Overall Survival Table 2. Neuroendocrine Tumours - Overall Survival N Observed Survival at risk 1 year 3 year 5 year 10 year 5 year CI 1 year 3 year 5 year 10 year 5 year CI NEUROENDOCRINE TUMOURS 3, [59.1 ; 62.8] [64.3 ; 68.3] Well differentiated endocrine tumours, carcinoid [24.9 ; 37.2] [27.7 ; 41.3] Well differentiated endocrine tumours, atypical carcinoid 13 * * * * * * * * * * Poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) [10.1 ; 16.2] [11.5 ; 18.4] Undifferentiated carcinoma of oesophagus 23 * * * * * * * * * * Endocrine carcinoma of thyroid gland [63.3 ; 79.1] [67.7 ; 84.6] Well differentiated not functioning endocrine carcinoma of pancreas and digestive tract 1, [71.9 ; 76.3] [78.2 ; 83.1] Well differentiated functioning endocrine carcinoma of pancreas and digestive tract 23 * * * * * * * * * * Endocrine carcinoma of skin Neuroendocrine tumours have a rather good prognosis, with a 5-year relative survival of 66.3%. There is a big difference in the different histological subtypes. Well-differentiated not functioning endocrine carcinoma of pancreas and digestive tract and endocrine carcinoma of the thyroid gland have the best prognosis. 4
5 Poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) have the worst prognosis Survival by Sex Table 3. Neuroendocrine Tumours - Survival by Sex N Observed Survival Males at risk 1 year 3 year 5 year 5 year CI 1 year 3 year 5 year 5 year CI NEUROENDOCRINE TUMOURS 1, [48.3 ; 54.0] [53.5 ; 59.8] Well differentiated endocrine tumours, carcinoid [15.5 ; 31.0] [17.2 ; 34.3] Well differentiated endocrine tumours, atypical carcinoid 5 * * * * * * * * Poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) [6.1 ; 12.8] [7.0 ; 14.8] Undifferentiated carcinoma of oesophagus 9 * * * * * * * * Endocrine carcinoma of thyroid gland [54.2 ; 78.9] [57.9 ; 84.4] Well differentiated not functioning endocrine carcinoma of pancreas and digestive tract [66.8 ; 73.5] [73.9 ; 81.3] Well differentiated functioning endocrine carcinoma of pancreas and digestive tract 9 * * * * * * * * Endocrine carcinoma of skin N Observed Survival Females at risk 1 year 3 year 5 year 5 year CI 1 year 3 year 5 year 5 year CI NEUROENDOCRINE TUMOURS 1, [66.7 ; 71.5] [71.7 ; 76.8] Well differentiated endocrine tumours, carcinoid [29.9 ; 48.5] [33.4 ; 54.1] Well differentiated endocrine tumours, atypical carcinoid 8 * * * * * * * * Poorly differentiated endocrine carcinoma (lung small cell carcinoma and skin excluded) [13.8 ; 25.2] [15.5 ; 28.3] Undifferentiated carcinoma of oesophagus 14 * * * * * * * * Endocrine carcinoma of thyroid gland [63.1 ; 83.4] [67.4 ; 89.1] Well differentiated not functioning endocrine carcinoma of pancreas and digestive tract [74.7 ; 80.5] [80.2 ; 86.4] Well differentiated functioning endocrine carcinoma of pancreas and digestive tract 14 * * * * * * * * Endocrine carcinoma of skin Regardless of the histological subgroup, prognosis is always better in females than males. Poorly differentiated endocrine carcinoma in male is the worst prognostic subgroup. Well-differentiated not functioning endocrine carcinoma of pancreas and digestive tract in female is the best prognostic subgroup Survival by Age Group Figure 3. Neuroendocrine Tumours - by Age Group 5
6 Relative survival is prognostically related with age: older patients have a poorer 5-year relative survival than younger patients. Figure 4. Well-differentiated Endocrine Tumours (Carcinoid), Poorly Differentiated Endocrine Carcinoma (Lung Small Cell Carcinoma and Skin Excluded), Endocrine Carcinoma of Thyroid Gland and Welldifferentiated Not Functioning Endocrine Carcinoma of Pancreas and Digestive Tract - by Age Group * Survival for patients of 75 years and older is not calculated because the number of patients at risk is below 35 For most subtypes, there is a clear age-dependent effect on relative survival. This is not true for endocrine carcinoma of thyroid gland, where patients of 0-54 years have almost the same prognosis as patients of years. 6
7 1.4.4 Survival by Stage Figure 5. Neuroendocrine Tumours - by Stage Prognosis depends on the stage of the disease: the more extensive the disease is, the worse the prognosis. Stage I and II disease have a good prognosis, with a 5-year relative survival of 95.6% and 86.6% respectively. Stage IV has the worst prognosis, with 5-year relative survival rates of less than 40%. Figure 6. Poorly Differentiated Endocrine Carcinoma (Lung Small Cell Carcinoma and Skin Excluded) and Well-differentiated Not Functioning Endocrine Carcinoma of Pancreas and Digestive Tract - Relative Survival by Stage * Survival for stage I-III is not calculated because the number of patients at risk for each of these stages is below 35. Because a great majority of patients with a neuroendocrine cancers are diagnosed with a well-differentiated non-functioning endocrine carcinoma of the pancreas and digestive tract, survival by stage group is very similar to the survival rates for all neuroendocrine tumours together. 7
8 2. Carcinoma of Endocrine Organs 2.1 General Results Table 4. Carcinoma of Endocrine Organs: Incidence, Trends, Survival Flemish Region Incidence Trend Survival Both Sexes EAPC R/C N CR WSR Avg Age % p-value N at risk 5yr (%) CARCINOMA OF ENDOCRINE ORGANS R 2, < , Carcinomas of pituitary gland R * Carcinomas of thyroid gland R 2, < , Carcinomas of parathyroid gland R * Carcinoma of adrenal gland R Males EAPC Relative survival R/C N CR WSR Avg Age % p-value N at risk 5yr (%) CARCINOMA OF ENDOCRINE ORGANS R < Carcinomas of pituitary gland R * * 11 * Carcinomas of thyroid gland R < Carcinomas of parathyroid gland R * Carcinoma of adrenal gland R Females EAPC Relative survival R/C N CR WSR Avg Age % p-value N at risk 5yr (%) CARCINOMA OF ENDOCRINE ORGANS C 2, < , Carcinomas of pituitary gland R * Carcinomas of thyroid gland C 1, , Carcinomas of parathyroid gland R * * 4 * Carcinoma of adrenal gland R R/C: Rare or common CR: Crude rate (N/100,000 person years) WSR: age-standardised rate, using the world population (N/100,000 person years) EAPC: estimated annual percentage change RS: relative survival AvgAge: average age at diagnosis 2.2 Incidence 2,933 new carcinoma of the endocrine organs are diagnosed in the Flemish Region between 2001 and The male/female ratio is 0.4. RARECARE differentiates between four rare entities: o Only 27 cases of carcinoma of pituitary gland are diagnosed in the Flemish Region between 2001 and The male/female ratio is 1.0. o Thyroid carcinoma is the most common carcinoma of endocrine organs (89%). The male/female ratio is 0.3. o Carcinomas of parathyroid gland account for 20 new cases. o Adrenal gland carcinomas represent 110 new diagnoses; The male/female ratio is
9 Figure 7. Carcinomas of Endocrine Organs: Age Specific Incidence by Sublocalisation and Caricnomas of Thyroid Gland: Age Specific Incidence by Sex, Flemish Region Carcinoma of adrenal gland is also observed in children and young adults, although the highest rates occur in the elderly. Thyroid carcinoma already occurs at an early age. In females the incidence rates increase rapidly from the age of 15 years to reach a peak around the age of 60 years. In males, the age specific incidence rates increase more gradually without showing a clear peak. Figure 8. Carcinomas of Thyroid Gland: Stage Distribution by Histology and Sex Information on stage is available in about 75% of all new diagnoses. Females have a prognostic more favourable stage distribution than males. Papillary thyroid carcinoma has the prognostic best stage distribution, anaplastic carcinoma has a very poor prognosis and is always diagnosed as stage IV. 9
10 2.3 Trends Figure 9. Carcinomas of Thyroid Gland: Age-Standardised Incidence by Age Group in Males and Females (three year moving average) Significant increases are observed for thyroid gland carcinoma in every age group in both sexes. 2.4 Survival Overall Survival Table 5. Carcinoma of Endocrine Organs - Overall Survival N Observed Survival at risk 1 year 3 year 5 year 10 year 5 year CI 1 year 3 year 5 year 10 year 5 year CI CARCINOMA OF ENDOCRINE ORGANS 2, [80.3 ; 83.5] [84.3 ; 87.6] Carcinomas of pituitary gland 23 * * * * * * * * * * Carcinomas of thyroid gland 2, [83.1 ; 86.2] [87.0 ; 90.2] Carcinomas of parathyroid gland 18 * * * * * * * * * * Carcinoma of adrenal gland [29.3 ; 49.6] [31.1 ; 52.7] Thyroid gland cancer has a good prognosis, with a 5-year relative survival of more than 85%. Inversely, prognosis is worse for adrenal gland carcinoma, for which the 5-year relative survival is 42% Survival by Sex Table 6. Carcinoma of Endocrine Organs - Survival by Sex N Observed Survival Males at risk 1 year 3 year 5 year 5 year CI 1 year 3 year 5 year 5 year CI CARCINOMA OF ENDOCRINE ORGANS [71.2 ; 77.9] [76.5 ; 83.7] Carcinomas of pituitary gland 11 * * * * * * * * Carcinomas of thyroid gland [75.2 ; 82.1] [80.6 ; 88.0] Carcinomas of parathyroid gland 14 * * * * * * * * Carcinoma of adrenal gland [23.0 ; 51.1] [24.7 ; 55.0] N Observed Survival Females at risk 1 year 3 year 5 year 5 year CI 1 year 3 year 5 year 5 year CI CARCINOMA OF ENDOCRINE ORGANS 1, [82.8 ; 86.3] [86.3 ; 89.9] Carcinomas of pituitary gland 12 * * * * * * * * Carcinomas of thyroid gland 1, [84.8 ; 88.2] [88.2 ; 91.7] Carcinomas of parathyroid gland 4 * * * * * * * * Carcinoma of adrenal gland [27.5 ; 56.2] [28.7 ; 58.6] Prognosis for carcinoma of endocrine organs is much better in females than in males, with a pronounced difference in the survival rates. 10
11 2.4.3 Survival by Age Group Figure 10. Carcinoma of Endocrine Organs - by Age Groups Prognosis is inversely related with age. Survival of the age groups 0-44 years and years is almost comparable. The patients of 60 years and older have a much worse prognosis. Figure 11. Carcinomas of Thyroid Gland - by Age Groups Because a great majority of all patients with a carcinoma of endocrine organs are diagnosed with a thyroid gland carcinoma, survival by age group is very similar to the rates for all carcinoma of endocrine organs together. 11
12 2.4.4 Survival by Stage Figure 12. Carcinoma of Endocrine Organs - by Stage Prognosis is very good in early stage carcinomas of endocrine organs, with a 5-year relative survival of more than 90% for all the stage I, II, III and X tumours. Stage IV tumours have a much worse prognosis. Their 5-year relative survival is less than 35%. Figure 13. Carcinomas of Thyroid Gland - by Stage Because a great majority of all patients with a carcinoma of endocrine organs are diagnosed with a thyroid gland carcinoma, survival by stage for this subtype is very similar to the rates for all carcinoma of endocrine organs together. 12
Rare Tumours of Male Genital Organs
Rare Tumours of Male Genital Organs 1. Epithelial Tumours of Prostate 1.1 General Results Table 1. Epithelial Tumours of Prostate: Incidence, Trends, Survival Flemish Region 2001-2010 Incidence Trend Survival
Rare Breast Tumours. 1. Breast Tumours. 1.1 General Results. 1.2 Incidence
Rare Breast Tumours 1. Breast Tumours 1.1 General Results Table 1. Epithelial Tumours of Breast: Incidence, Trends, Survival Flemish Region 2001-2010 Incidence Trend Survival Females EAPC Relative survival
Oral Cavity. 1. Introduction. 1.1 General Information and Aetiology. 1.2 Diagnosis and Treatment
Oral Cavity 1. Introduction 1.1 General Information and Aetiology The oral cavity extends from the lips to the palatoglossal folds and consists of the anterior two thirds of the tongue, floor of the mouth,
1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates
2 1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates Table 1: Testicular Cancer: Average age at diagnosis, number of new cancer diagnoses (N), crude rate (CR), age-standardised incidence
1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates
2 1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates Table 1: Testicular Cancer: Average age at diagnosis, number of new cancer diagnoses (N), crude rate (CR), age-standardised incidence
1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates
2 1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates Table 1: Colorectal Cancer: Average age at diagnosis, number of new cancer diagnoses (N), crude rate (CR), age-standardised incidence
1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates
2 1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates Table 1: Bladder Cancer: Average age at diagnosis, number of new cancer diagnoses (N), crude rate (CR), age-standardised incidence
1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates
2 1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates Table 1: Colorectal Cancer: Average age at diagnosis, number of new cancer diagnoses (N), crude rate (CR), age-standardised incidence
1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates
2 1. Cancer Incidence 1.1. Number of new diagnoses and incidence rates Table 1: Malignant Melanoma: Average age at diagnosis, number of new cancer diagnoses (N), crude rate (CR), age-standardised incidence
Tumor markers. Chromogranin A. Analyte Information
Tumor markers Chromogranin A Analyte Information -1-2018-04-22 Chromogranin A Introduction Chromogranin A (CgA) is a 439-amino acid protein with a molecular weight of 48 to 60 kda, depending on glycosylation
SCOPE TODAYS SESSION. Case 1: Case 2. Basic Theory Stuff: Heavy Stuff. Basic Questions. Basic Questions
MONDAY TEACHING SCOPE TODAYS SESSION Case 1: Basic Questions Case 2 Basic Questions Basic Theory Stuff: AJCC TNM + Stage Group for Carcinoid of the Appendix Management of Carcinoid of the Appendix (NCCN)
Ch. 39 Endocrine System
Ch. 39 Endocrine System The Endocrine System The endocrine system is made up of glands that release their products into the bloodstream These products deliver messages throughout the body Hormones Hormones
Chibueze Onyemkpa 1, Alan Davis 1, Michael McLeod 1, Tolutope Oyasiji 1,2. Original Article
Original Article Typical carcinoids, goblet cell carcinoids, mixed adenoneuroendocrine carcinomas, neuroendocrine carcinomas and adenocarcinomas of the appendix: a comparative analysis of survival profile
Trends in Cancer Survival in Scotland
Scottish Cancer Intelligence Unit Trends in Cancer Survival in Scotland - Trends in survival are presented for the half million adult cancer patients diagnosed in Scotland between and. The Results show,
Case year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
incidence rate x 100,000/year
Tier R=rare C=common Cancer Entity European crude and age adjusted incidence by cancer, years of diagnosis 2000 and 2007 Analisys based on 83 population-based cancer registries * applying the European
Pitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD
Pitfalls in thyroid tumor pathology Prof.Valdi Pešutić-Pisac MD, PhD Too many or... Tumour herniation through a torn capsule simulating capsular invasion fibrous capsule with a sharp discontinuity, suggestive
Lip. 1. Introduction. 1.1 General Information and Aetiology
Lip 1. Introduction 1.1 General Information and Aetiology Lips are the external part of the mouth. They are bounded externally by facial skin. On the oral cavity side, they are continuous with buccal mucosa
Case 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018
1 2018 Grade PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgements Donna Hansen, CCR Jennifer Ruhl, NCI SEER Introduction 3 Histologic Type vs. Grade Credit: Dr. Kay Washington
Lab Exercise Endocrine System
Lab Exercise Endocrine System Name Date Materials: Human torso model Compound light microscope Prepared slides of the pituitary gland, pineal gland, thyroid gland, parathyroid glands, thymus gland, adrenal
Nasopharynx. 1. Introduction. 1.1 General Information and Aetiology
Nasopharynx 1. Introduction 1.1 General Information and Aetiology The nasopharynx is the uppermost, nasal part of the pharynx. It extends from the base of the skull to the upper surface of the soft palate.
APPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
What s New for 8 th Edition
What s New for 8 th Edition KCR 2018 SPRING TRAINING Overview What s New New Chapters for 8 th Editions Chapters That Split in 8 th Edition Merged 8 th Edition Chapters Blanks vs Xs How to Navigate Through
Cancer in the Northern Territory :
Cancer in the Northern Territory 1991 21: Incidence, mortality and survival Xiaohua Zhang John Condon Karen Dempsey Lindy Garling Acknowledgements The authors are grateful to the many people, who have
Management of thyroid cancer in the Northern and Yorkshire region,
Management of thyroid cancer in the Northern and Yorkshire region, 2009-2010 About Public Health England Public Health England s mission is to protect and improve the nation s health and to address inequalities
Hypopharynx. 1. Introduction. 1.1 General Information and Aetiology
Hypopharynx 1. Introduction 1.1 General Information and Aetiology The human pharynx is the part of the throat situated between the nasal cavity and the esophagus and can be divided into three parts: the
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not recorded =191 (non-melanoma skin cancer) treated as not recorded
Squamous Cell Carcinoma of Thyroid: possible thymic origin, so-called ITET/CASTLE 2012/03/22
Squamous Cell Carcinoma of Thyroid: possible thymic origin, so-called ITET/CASTLE 2012/03/22 History of ITET/CASTLE First Report Gross Appearance and Prognosis 1) Miyauchi A et al: Intrathyroidal epithelial
Vagina. 1. Introduction. 1.1 General Information and Aetiology
Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.
Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 15 (2006) 681 685 Index Note: Page numbers of article titles are in boldface type. A Ablative therapy, for liver metastases in patients with neuroendocrine tumors, 517 with radioiodine
FAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN
Int. J. Cancer: 94, 444 448 (2001) 2001 Wiley-Liss, Inc. FAMILIAL CARCINOID TUMORS AND SUBSEQUENT CANCERS: A NATION-WIDE EPIDEMIOLOGIC STUDY FROM SWEDEN Kari HEMMINKI* and Xinjun LI Department of Biosciences
WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:
WLH Tumor Frequencies between cohort enrollment and 31-Dec 2012 DESCRIPTION Below the Women Lifestyle and Health tumor frequencies are tabulated according to: Benign =171 (Cervix uteri) treated as not
CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996
CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996 CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996 Menzies Centre For Population Health Research Editors: Dace Shugg, Terence Dwyer and Leigh Blizzard Publication
Trends in Cancer Survival in NSW 1980 to 1996
Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August
CEA (CARCINOEMBRYONIC ANTIGEN)
(CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant
Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL
Description of Measure OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL This measure calculates the percentage of abdomen studies that are performed with and without contrast out of all abdomen studies performed
Endocrine Glands and Hormones "What are endocrine glands and what do they make?
Endocrine Glands and Hormones "What are endocrine glands and what do they make? Model 1:Development of glands. Exocrine Gland Endocrine Gland Critical thinking questions 1. Based on the model, which of
Enterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Update of mixed tumours of the GI tract, the pancreas and the liver Introduction to the concept of mixed tumours and clinical implication Jean-Yves SCOAZEC Surgical
Endocrine System Objectives
Component 3-Terminology in Healthcare and Public Health Settings Unit 7- Endocrine System Lecture 7a-Overview of the Endocrine System, Adrenal Glands and Pancreas This material was developed by The University
SUPPLEMENTARY INFORMATION
Supplementary Table 1 trials currently open for patients with pheochromocytoma and/or paraganglima (from trials.gov) www.clinicaltrials.gov; Active PPGL trials Status Of Sunitinib In Patients With Recurrent
Neuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:
H&N Neuroendocrine Neoplasms: Classification and Diagnostic Considerations Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Broad Classification: A. Epithelial:
Small cell neuroendocrine carcinoma icd 10
Small cell neuroendocrine carcinoma icd 10 1-10-2017 Free, official coding info for 2018 ICD - 10 -CM C34.90 - includes detailed rules, notes, synonyms, ICD -9- crosswalks, DRG. In most series, LCLC's
Fig. 59 Malignant phaeochromocytoma, hepatic metastasis.
Fig. 59 Malignant phaeochromocytoma, hepatic metastasis. X 120 Hyperte nsion Fig. 60 Malignant sympathetic paraganglioma, lymph node metastasis Primary in bladder. x 1 20 Hypertension Fig. 61 Malignant
The Endocrine System and Reproduction
The Endocrine System and Reproduction ` Grade 9 Science 2011 Essential Questions How does the Endocrine system control body processes? What are the Endocrine glands? What do Endocrine glands do? What is
Chapter 21. Human Endocrine System
Chapter 21 Human Endocrine System Endocrine System Consist of endocrine glands that secrete hormones which regulate a wide range of activities in humans Hormones- are secreted by glands and diffuse directly
Endocrine system pathology
Endocrine system pathology Central endocrine system peripheral endocrine system: thyroid gland parathyroid gland pancreas adrenal glands Thyroid gland. the weight of normal thyroid gland is about 15 grams.
Cancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
10/24/2008. Surgery for Well-differentiated Thyroid Carcinoma- The Primary
Surgery for Well-differentiated Thyroid Carcinoma- The Primary Head and Neck Endocrine Surgery Department of Otolaryngology-Head and Neck Surgery, UCSF October 24-25, 2008 Robert A. Sofferman, MD Professor
EPITHELIAL TUMOURS OF OESOPHAGUS RARE EPITHELIAL TUMOURS OF STOMACH EPITHELIAL TUMOURS OF SMALL INTESTINE RARE EPITHELIAL TUMOURS OF COLON
RARE EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM 16% OF DIGESTIVE SYSTEM TUMOURS ARE RARE EPITHELIAL TUMOURS 2 262 271 EPITHELIAL TUMOURS OF OESOPHAGUS RARE EPITHELIAL TUMOURS OF STOMACH 81 1 % OF RARE
Cancer in Ireland : Annual Report of the National Cancer Registry
Cancer in Ireland 1994-213: Annual Report of the National Cancer Registry 215 Page 3 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard
Haematological malignancies in England Cancers Diagnosed Haematological malignancies in England Cancers Diagnosed
Northern and Yorkshire Cancer Registry and Information Service Haematological malignancies in England Cancers Diagnosed 2001-2008 Haematological 2001-2008 Malignancies www.nycris.nhs.uk www.nycris.nhs.uk
Lung Cancer and Mesothelioma Site Specific Clinical Reference Group Data Quality Report 2009
Lung Cancer and Mesothelioma Site Specific Clinical Reference Group Data Quality Report 9 Sharma P Riaz Karen M Linklater Henrik Møller Margreet Lüchtenborg Contents 1. Introduction... 1 2. Methods...
CODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
Calcitonin. 1
Calcitonin Medullary thyroid carcinoma (MTC) is characterized by a high concentration of serum calcitonin. Routine measurement of serum calcitonin concentration has been advocated for detection of MTC
Diagnostic Pathology Endocrine
Diagnostic Pathology Endocrine 1 / 6 2 / 6 3 / 6 Diagnostic Pathology Endocrine Diagnostic Pathology: Endocrine, 2nd Edition. Part of the highly regarded Diagnostic Pathology series, this updated volume
Diseases of the gastrointestinal system. H Awad Lecture 2: small intestine/ part 2 and appendix
Diseases of the gastrointestinal system H Awad Lecture 2: small intestine/ part 2 and appendix Malabsorption most important causes of malabsorption: Celiac disease tropical sprue Lactase deficiency Whipple
B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.
B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life. b. Deficiency of dietary iodine: - Is linked with a
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach Dr. Carol Farver Director, Pulmonary Pathology Pathology and Laboratory Medicine Institute Objectives Discuss
GENERAL ICD- C73: Thyroid cancer Page 2 of 15 ICD- C73: Malignant neoplasm of thyroid gland Period of diagnosis % Relative survival N=7,95 9
Munich Cancer Registry Incidence and Mortality Selection Matrix Homepage Deutsch ICD- C73: Thyroid cancer Survival Year of diagnosis 1988-1997 1998-215 Patients 953 7,13 Diseases 957 7,18 Cases evaluated
Histopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
APPLIED SCIENCE. Unit 4 Human physiology Suite. Cambridge TECHNICALS LEVEL 3. D/507/6151 Guided learning hours: 60. ocr.org.
2016 Suite Cambridge TECHNICALS LEVEL 3 APPLIED SCIENCE Unit 4 Human physiology D/507/6151 Guided learning hours: 60 Version 3 - September 2016 - black line indicates updated content ocr.org.uk/science
Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma
524 Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma A Population-Based, Nested Case Control Study Catharina Ihre Lundgren, M.D. 1,2 Per Hall, M.D., Ph.D. 1 Paul W. Dickman,
Histological Type. Morphological and Molecular Typing of breast Cancer. Nottingham Tenovus Primary Breast Cancer Study. Survival (%) Ian Ellis
Morphological and Molecular Typing of breast Cancer Ian Ellis Molecular Medical Sciences, University of Nottingham Department of Histopathology, Nottingham University Hospitals NHS Trust Histological Type
Hepatobiliary and Pancreatic Malignancies
Hepatobiliary and Pancreatic Malignancies Gareth Eeson MD MSc FRCSC Surgical Oncologist and General Surgeon Kelowna General Hospital Interior Health Consultant, Surgical Oncology BC Cancer Agency Centre
SOME USEFUL THINGS TO KNOW ABOUT HEAD AND NECK CANCER IN 2016
SOME USEFUL THINGS TO KNOW ABOUT HEAD AND NECK CANCER IN 2016 Ann Dingle Mid Cheshire Hospitals ENT Surgeon in a DGH with an interest in Head and Neck disease Cancer Lead Plan for today Facts and figures
Fast, automated, precise
Thermo Scientific B R A H M S / NSE Immunodiagnostic Assays Fast, automated, precise Neuroendocrine tumor markers on KRYPTOR Systems First and only fully automated CgA assay worldwide Shortest time to
Anatomy of the biliary tract
Harvard-MIT Division of Health Sciences and Technology HST.121: Gastroenterology, Fall 2005 Instructors: Dr. Jonathan Glickman Anatomy of the biliary tract Figure removed due to copyright reasons. Biliary
The International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
Lec.2 Histology Glandular Epithelium A gland 1. Endocrine Glands 2. Exocrine Glands Endocrine Glands Exocrine Glands
Lec.2 Histology Glandular Epithelium A gland is one or more cells that produce and secrete a specific product. The product is always a water-based fluid (aqueous) and usually contains proteins (the product
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
Somatuline Depot. Somatuline Depot (lanreotide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.27 Subject: Somatuline Depot Page: 1 of 5 Last Review Date: December 8, 2017 Somatuline Depot Description
Immunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy
Carcinoid Tumors: The Beginning and End. Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011
Carcinoid Tumors: The Beginning and End Surgical Oncology Update 2011 Chris Baliski MD, FRCS BC Cancer Agency, CSI October 21, 2011 1 st described by Oberndofer(1907) Karzinoide = cancer like Arise from
Endocrine Malignancies: A Five-Year Retrospective Analysis in a Tertiary Hospital
Philippine Journal of Internal Medicine Original Article Endocrine Malignancies: A Five-Year Retrospective Analysis in a Tertiary Hospital Celeste C. Ong-Ramos, M.D.*; Leila Sawadjaan, M.D.*; Michael L.
5/1/2009. Squamous Dysplasia/CIS AAH DIPNECH. Adenocarcinoma
Pathological Assessment of Diagnostic Specimens Keith Kerr Department of Pathology Aberdeen University Medical School Aberdeen Royal Infirmary Foresterhill, Aberdeen, Scotland, UK Tumours of the Lung:
Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
2018 Surgical Pathology Update: Diagnostic Pearls for the Practicing Pathologist - Volume II
Release Date: January 1, 15.25 AMA PRA Category 1 Credit(s) TM About This CME Teaching Activity This CME Activity is designed to provide a comprehensive review of soft tissue, gastrointestinal, genitourinary,
Icd-10 code for small cell lung cancer
P ford residence southampton, ny Icd-10 code for small cell lung cancer Non-small cell lung carcinomas are usually adenocarcinomas, squamous cell carcinomas, or large cell carcinomas. Metastatic carcinomas
Supplementary Online Content
Supplementary Online Content Henson KE, Brock R, Charnock J, Wickramasinghe B, Will O, Pitman A. Risk of suicide after cancer diagnosis in England. JAMA Psychiatry. Published online November 21, 2018.
The British Association of Endocrine and Thyroid Surgeons National Audit. D R Chadwick BAETS Audit Lead
The British Association of Endocrine and Thyroid Surgeons National Audit D R Chadwick BAETS Audit Lead Topics Summary of our audit; history, methodology and data fields Thoughts on thyroid-cancer specific
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
Appendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
THE ENDOCRINE SYSTEM. By Vinnie Partridge, Nicholas Young, and Mercedes Smith
THE ENDOCRINE SYSTEM By Vinnie Partridge, Nicholas Young, and Mercedes Smith WHAT IS THE ENDOCRINE SYSTEM? The Endocrine System, also referred to as the glandular system, is made up of multiple types of
WHO e TNM: Importanza della classificazione nell approccio terapeutico
WHO e TNM: Importanza della classificazione nell approccio terapeutico Marco Volante Mauro Papotti Dipartimento di Scienze Cliniche e Biologiche Ospedale San Luigi Orbassano, Torino Rare tumors Heterogeneous
The Endocrine System
The Endocrine System Exocrine glands Endocrine glands Hormone Pituitary gland Hypothalamus Thyroid Thyroxine Pancreas KEYWORDS Insulin Islets of Langerhans Goitre Thymus Thymosin What are glands? Exocrine
Update on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
What is the endocrine system?
Name: Class: Date: What is the endocrine system? Biology Gr11A Physiological regulation in mammals Your body depends on the endocrine system to stay healthy. This system has special organs called glands
Table of Contents Section I Pituitary and Hypothalamus 1. Development of the Pituitary Gland 2. Divisions of the Pituitary Gland and Relationship to
Table of Contents Section I Pituitary and Hypothalamus 1. Development of the Pituitary Gland 2. Divisions of the Pituitary Gland and Relationship to the Hypothalamus 3. Blood Supply of the Pituitary Gland
Thyroid Cancer in New Mexico
Thyroid Cancer in New Mexico Time Trends and Surgical Treatment Preferences Ihsan Mahdi MD MPH Introduction The incidence of thyroid cancer incidence is increasing more rapidly than any other malignancy
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
Endocrinology BLOCK (ENDO 225)
Attachment 2 (g) Kingdom of Saudi Arabia The National Commission for Academic Accreditation & Assessment COURSE REPORT Endocrinology BLOCK (ENDO 225) 1433-1434 (2012-2013) To be completed by course instructors
The Endocrine System. By Carl Antiado, Marco Habana, Cameron Loewen, and Nikki Ooka
The Endocrine System By Carl Antiado, Marco Habana, Cameron Loewen, and Nikki Ooka Standards 2.C.2 : Organisms respond to changes in their external environments. 4.A.4: Organisms exhibit complex properties
CHAPTER 3 DEATHS. Stephen McDonald Leonie Excell Brian Livingston
CHAPTER 3 DEATHS Stephen McDonald Leonie Excell Brian Livingston DEATHS ANZDATA Registry 2008 Report INTRODUCTION AUSTRALIA NEW ZEALAND The total number of deaths was 1,452 (15.4 deaths per 100 patient
Women s Health in General Practice Symposium 2015 Thyroid & Parathyroid Cases
Women s Health in General Practice Symposium 2015 Thyroid & Parathyroid Cases Bill Fleming Epworth Freemasons Hospital 1 Common Endocrine Presentations anatomical problems thyroid nodule / goitre embryological
Hazelinks - Cancer incidence analysis (First data extraction)
Hazelinks - Cancer incidence analysis (First data extraction) Authors Prof Malcolm Sim Ms Christina Dimitriadis Dr Caroline Gao Mr Anthony Del Monaco 1 1 Contents Abbreviations... 3 Executive Summary...
Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.
Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition Procedures Cytology (No Accompanying Checklist)